Protalix (PLX) Reports Publication of Encouraging Data from Taliglucerase Phase III in Gaucher Disease
Tweet Send to a Friend
Protalix BioTherapeutics, Inc. (AMEX: PLX), reports an article entitled "Pivotal Trial with Plant-Cell–Expressed Recombinant Glucocerebrosidase, taliglucerase alfa, a Novel Enzyme ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
